EUVIMEDEUVIMED entdecken
Crossref

Effectiveness and dose stability of opioids in patients with restless leg syndrome: 5-year findings from the National Restless Legs Syndrome Opioid Registry

John W Winkelman, Adysn Kilty, Benjamin Wipper iD, Jordana Zackon, Justin Sherfey

SLEEP · 2026

DOI: 10.1093/sleep/zsag008 ↗

Kurz gefasst

Fachartikel in der Zeitschrift SLEEP, 2026. Verfasst von John W Winkelman und 4 weiteren Autor:innen. Beteiligte Einrichtung: Massachusetts General Hospital, Department of Psychiatry, Boston, Massachusetts, United States. Hauptthemen laut MEDLINE: Restless Legs Syndrome, Analgesics, Opioid. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study Objectives Large long-term assessments of opioid effectiveness and dose stability for those with dopamine agonist augmentation of restless legs syndrome (RLS) are lacking. We present 5-year longitudinal findings from the National RLS Opioid Registry.

Methods

Five-hundred participants taking opioids for RLS were interviewed at baseline about RLS symptoms, opioid medications and doses, sleep, and mental health. Participants subsequently completed online surveys every 6 months. Changes from baseline to 5-year follow-up in morphine milligram equivalents (MMEs), excluding those taking buprenorphine, were evaluated by group-based trajectory modeling. Independent associations with opioid dose changes were determined using multiple logistic regression.

Results

At 5 years of follow-up, 410 (364 excluding any taking buprenorphine) participants remained for this analysis. Most participants are female (57.1 per cent) and white (98.3 per cent), with an average age of 64.7 (±10.6) and 88.8 per cent had a history of dopamine agonist augmentation. The median daily MME at 5 years was 37.5 (equivalent to methadone 8.0 mg or oxycodone 25.0 mg), an increase of 7.5 MME from baseline. Opioid doses increased from baseline to 5 years in 49.5 per cent of participants and decreased in 20.0 per cent of participants. Group-based trajectory analysis identified four distinct groups: decrease (3.4 per cent of participants; average MME change = −15.7 ± 12.4), no/little change (66.1 per cent of participants; average MME change = 1.5 ± 8.0), small increase (23.9 per cent of participants; average MME change = 22.0 ± 11.6), and large increase (3.4 per cent of participants; average MME change = 49.2 ± 18.7). RLS severity was stable from baseline (13.3 ± 9.6) to 5 years (13.1 ± 9.0) according to the International Restless Legs Syndrome Study Group Severity Scale.

Conclusions

Opioid doses in augmented RLS remain largely stable over 5 years of follow-up. Low-dose opioids provide an effective long-term option for augmented RLS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Restless Legs SyndromeAnalgesics, OpioidHumansFemaleRegistriesMaleMiddle AgedLongitudinal StudiesAgedDopamine AgonistsDose-Response Relationship, DrugBuprenorphineMethadoneTreatment Outcome

Stichwörter der Autor:innen

methadoneobservational studyopioidsregistryrestless legs syndrome

Substanzen

Analgesics, OpioidDopamine AgonistsBuprenorphineMethadone

Autor:innen und Institutionen

  • Massachusetts General Hospital, Department of Psychiatry, Boston, Massachusetts, United States.
  • Harvard Medical School, Department of Psychiatry, Boston, Massachusetts, United States.
  • George Washington University, School of Medicine and Health Sciences, Washington, DC, United States.
  • Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Boston, Massachusetts, United States.
  • Tufts University School of Medicine, Boston, Massachusetts, United States.

ORCID-Profile: Benjamin Wipper

Zitieren

APA

Winkelman, J. W., Kilty, A., Wipper, B., Zackon, J., & Sherfey, J. (2026). Effectiveness and dose stability of opioids in patients with restless leg syndrome: 5-year findings from the National Restless Legs Syndrome Opioid Registry. SLEEP. https://doi.org/10.1093/sleep/zsag008

Vancouver

Winkelman JW, Kilty A, Wipper B, Zackon J, Sherfey J. Effectiveness and dose stability of opioids in patients with restless leg syndrome: 5-year findings from the National Restless Legs Syndrome Opioid Registry. SLEEP. 2026. doi:10.1093/sleep/zsag008

BibTeX
@article{Winkelman2026,
  author = {Winkelman, John W and Kilty, Adysn and Wipper, Benjamin and Zackon, Jordana and Sherfey, Justin},
  title = {Effectiveness and dose stability of opioids in patients with restless leg syndrome: 5-year findings from the National Restless Legs Syndrome Opioid Registry},
  journal = {SLEEP},
  year = {2026},
  doi = {10.1093/sleep/zsag008}
}
Kostenlos starten →